Get started
Author

Michael Northend

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
2022 · Michael Northend, William Wilson, et al. · Blood Advances · 43
PDF
International Prognostic Score for Nodular Lymphocyte–Predominant Hodgkin Lymphoma
2024 · Michael Sargent Binkley, Jamie E. Flerlage, et al. · Journal of Clinical Oncology · 24
Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial
2025 · Michael Northend, William Wilson, et al. · The Lancet Haematology · 19
Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment without Detrimental Impact Following Next Line of Therapy
2022 · Michael Northend, William Wilson, et al. · Blood · 14
Novel Therapy Approaches to Follicular Lymphoma
2021 · Michael Northend, William Townsend · Drugs · 7
Polatuzumab Vedotin With Bendamustine and Rituximab for Relapsed/refractory High‐grade B‐cell Lymphoma: the Uk Experience
2021 · M. Northend, W. Wilson, et al. · Hematological Oncology · 3
Real World Outcomes and Responses to Second‐line Therapy in Relapsed/refractory Hodgkin Lymphoma: a Multicentre Uk Study
2021 · R. Shotton, A. A. Kirkwood, et al. · Hematological Oncology · 3
PDF
Outcomes of patients over 70 years treated with brexu-cel for R/R mantle cell lymphoma: a study from the CTIWP of EBMT
2026 · Nicole Santoro, Jarl Edouard Mooyaart, et al. · Blood Advances · 2
PDF
Outcomes of second‐line axicabtagene ciloleucel for large B‐cell lymphoma in the UK
2026 · Andrea Kuhnl, Amy A. Kirkwood, et al. · HemaSphere · 2
PDF
Multi-Centre Real-World Outcomes of Large B-Cell Lymphoma Patients Treated with 2L Axicabtagene Ciloleucel in the UK
2024 · Andrea Kuhnl, Amy A Kirkwood, et al. · Blood · 2
PDF
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
2023 · Michael S. Binkley, Jamie E. Flerlage, et al. · SSRN Electronic Journal · 2
Response‐adapted chimeric antigen receptor T cell (CAR‐T)–sparing consolidation radiotherapy in high‐risk large B‐cell lymphoma (LBCL): Results of the prospective RESTART protocol
2026 · N. G. Mikhaeel, S. Bouziana, et al. · British Journal of Haematology · 1
PDF
Historical outcomes for patients with stage IA NLPHL: Global NLPHL One Working Group retrospective analyses
2026 · Jamie E. Flerlage, Dennis A. Eichenauer, et al. · Blood Advances · 1
PDF
CAR-T therapy for relapsed/refractory large B-cell lymphoma in people living with HIV: efficacy, toxicity and treatment considerations.
2026 · Angela Hwang, Amy A. Kirkwood, et al. · Haematologica · 1
PDF
MTV ‐guided radiotherapy bridging in large B‐cell lymphoma patients receiving CD19 CAR T‐cell therapy
2025 · Andrea Kuhnl, S. Bouziana, et al. · British Journal of Haematology · 1
PDF
Updated Results of RESTART Protocol (RadiothErapy bridging and conSolidaTion for CAR-T) in Large B-cell Lymphoma
2025 · G. Mikhaeel, S. Bouziana, et al. · International Journal of Radiation Oncology*Biology*Physics · 1
PDF
23 | Radiotherapy Improves Progression‐free Survival for Stage Ia Nlphl: a Retrospective Report From the Global Nlphl One Working Group (glow)
2025 · J. Flerlage, D. A. Eichenauer, et al. · Hematological Oncology · 1
PDF
The Prognostic Impact of Clinical Factors and Immunoarchitectural Patterns for Nodular Lymphocyte‐predominant Hodgkin Lymphoma: an International Study by Glow
2023 · M. S. Binkley, J. E Flerlage, et al. · Hematological Oncology · 1
PDF
‘A Bridge Too CAR? Who Benefits from Bridging Therapy in 2026?’ [“Impact of Bridging Response on Outcomes after CD19 CAR T-Cell Therapy in Large B-Cell Lymphoma” – Wills et al. Transplant Cell Ther 2026]
2026 · Michael Northend, Claire Roddie · Transplantation and Cellular Therapy
Early PET response predicts the risk of relapse after 2L axi-cel in large B-cell lymphoma
2026 · Andrea Kuhnl, Amy A. Kirkwood, et al. · Blood Advances
782 | Game Set and Match for Car‐t in Dlbcl? Why Treatment Bias Against Bispecific Antibodies May Make Matched Real‐world Comparisons Uninterpretable
2025 · A. A. Kirkwood, C. Roddie, et al. · Hematological Oncology
PDF
459 | Outcomes of Second‐line Axicabtagene Ciloleucel for Large B‐cell Lymphoma in the Uk
2025 · A. Kuhnl, A. A. Kirkwood, et al. · Hematological Oncology
PDF
15 | Early Pet Response Predicts Risk of Relapse After 2l Axi‐cel in Large B‐cell Lymphoma
2025 · A. Kuhnl, A. A Kirkwood, et al. · Hematological Oncology
PDF
2843 Updated results of a comprehensive prospective protocol of radiotherapy bridging and consolidation for CAR-T in large B-cell lymphoma (RESTART)
2025 · Stella Bouziana, George Mikhaeel, et al. · Radiotherapy and Oncology
Bendamustine Plus Brentuximab Has Superior Efficacy to Brentuximab Monotherapy As Third-Line Treatment for Classical Hodgkin Lymphoma: A Real-World, Multicentre UK Analysis
2023 · Rohan Shotton, Amy A Kirkwood, et al. · Blood
PDF
Works count: 31
Citation count: 128
H-index: 5
I10-index: 4
Year
Topic
Type